Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Instituto do Cancer do Estado de São Paulo
Fudan University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Endeavor Biomedicines, Inc.
University Hospital, Lille
Dana-Farber Cancer Institute
Fundación GECP
H. Lee Moffitt Cancer Center and Research Institute
Brigham and Women's Hospital
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University of Pittsburgh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Azienda USL Reggio Emilia - IRCCS
University Hospital Southampton NHS Foundation Trust
University of Chicago